Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member
tabling member	label

Search

1652821

registered interest
date	13/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Semaglutide
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to take steps to prioritise type 2 diabetic patients for Ozempic prescriptions; and if he will make a statement.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	193849
answer	answer is ministerial correction date of answer 18/07/2023 answer text <p>There are global supply issues with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are licensed for treating patients with type 2 diabetes, including the branded medicine Ozempic. This appears to be largely driven by off-label prescribing for weight loss, which has led to shortages of these medicines for patients with type 2 diabetes.</p><p>We have issued guidance in the form of a Medicine Supply Notification (MSN), addressing all GLP-1 RAs, advising healthcare professionals on how to manage patients requiring these medicines. We are considering whether further communications are required.</p><p>The Government expects all providers of healthcare services, whether National Health Service or private, and all those with responsibility for prescribing to take appropriate account of national guidance such as MSNs. The guidance is clear that these medicines should only be prescribed for the treatment of type 2 diabetes, in order to protect supply for diabetes patients. Medicines which are solely licensed to treat type 2 diabetes should not be routinely prescribed for weight loss.</p><p>We are working closely with national diabetes specialists, the NHS, wholesalers, all manufacturers of these medicines and the relevant regulatory bodies and agencies to address this problem and to understand how we can help ensure type 2 diabetic patients continue to get access to treatment.</p> answering member constituency Colchester answering member printed Will Quince question first answered 18/07/2023 09:19:13 answering member 4423 label Biography information for Will Quince
tabling member	1453 label Biography information for Andrew Selous

1646317

registered interest
date	21/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lyme Disease: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the (a) capacity and (b) capability of the NHS to diagnose Lyme disease.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	190515
answer	answer is ministerial correction date of answer 30/06/2023 answer text <p>The Government has not conducted an assessment of the adequacy of National Health Service capability and capacity to diagnose Lyme disease or a comparative assessment of best practice in the diagnosis and treatment of this disease in the United Kingdom, the United States and Germany.</p><p>Diagnosis of Lyme disease in England and Wales is conducted by the Rare and Imported Pathogens Laboratory (RIPL). RIPL provides Lyme polymerase chain reaction PCR testing and a comprehensive serological panel which has been fully validated to UK Accreditation Service standards.</p><p>Published research, for example the VICTORY study in Lancet ID, indicates that cellular tests for Lyme borreliosis used by many private laboratories in Europe have a high false positive rate. A copy of the VICTORY study in Lancet ID, is available at the following link:</p><p><a href="https://doi.org/10.1016/S1473-3099(22)00205-5.)" target="_blank">https://doi.org/10.1016/S1473-3099(22)00205-5.)</a></p><p>UK Health Security Agency published accompanying guidance documents on Lyme disease in July 2018, which describe the clinical signs and symptoms and are consistent with the National Institute for Health and Care Excellence guidance. The guidance is available at the following link:</p><p><a href="https://www.gov.uk/guidance/lyme-disease-management-and-prevention" target="_blank">https://www.gov.uk/guidance/lyme-disease-management-and-prevention</a></p><p>Services for the treatment of Lyme disease are commissioned locally. These services are the responsibility of integrated care board and general practitioners use their professional judgement in diagnosing and treating this condition.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 30/06/2023 13:41:50 answering member 4492 label Biography information for Maria Caulfield
tabling member	1453 label Biography information for Andrew Selous

1646319

registered interest
date	21/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lyme Disease: Germany and USA
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of best practice for the (a) diagnosis and (b) treatment of Lyme disease in the (i) United States and (ii) Germany.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	190516
answer	answer is ministerial correction date of answer 30/06/2023 answer text <p>The Government has not conducted an assessment of the adequacy of National Health Service capability and capacity to diagnose Lyme disease or a comparative assessment of best practice in the diagnosis and treatment of this disease in the United Kingdom, the United States and Germany. Diagnosis of Lyme disease in England and Wales is conducted by the Rare and Imported Pathogens Laboratory (RIPL). RIPL provides Lyme polymerase chain reaction PCR testing and a comprehensive serological panel which has been fully validated to UK Accreditation Service standards.</p><p>Published research, for example the VICTORY study in Lancet ID, indicates that cellular tests for Lyme borreliosis used by many private laboratories in Europe have a high false positive rate. A copy of the VICTORY study in Lancet ID, is available at the following link: https://doi.org/10.1016/S1473-3099(22)00205-5.)</p><p>UK Health Security Agency published accompanying guidance documents on Lyme disease in July 2018, which describe the clinical signs and symptoms and are consistent with the National Institute for Health and Care Excellence guidance. The guidance is available at the following link: https://www.gov.uk/guidance/lyme-disease-management-and-prevention</p><p>Services for the treatment of Lyme disease are commissioned locally. These services are the responsibility of integrated care board and general practitioners use their professional judgement in diagnosing and treating this condition.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 30/06/2023 13:41:39 answering member 4492 label Biography information for Maria Caulfield
tabling member	1453 label Biography information for Andrew Selous

1646021

registered interest
date	20/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lyme Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make (a) an assessment of the adequacy of the NHS (i) capacity and (ii) capability to diagnose Lyme disease and (b) a comparative assessment of best practice in the diagnosis and treatment of Lyme disease in (A) the UK, (B) the US and (C) Germany.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	190272
answer	answer is ministerial correction date of answer 10/07/2023 answer text <p>The Government has not conducted an assessment of the adequacy of National Health Service capability and capacity to diagnose Lyme disease or a comparative assessment of best practice in the diagnosis and treatment of this disease in the United Kingdom, the United States, and Germany.</p><p>Diagnosis of Lyme disease in England and Wales is conducted by the Rare and Imported Pathogens Laboratory (RIPL). RIPL provides Lyme polymerase chain reaction PCR testing and a comprehensive serological panel which has been fully validated to UK Accreditation Service standards.</p><p>Services for the treatment of Lyme disease are commissioned locally. These services are the responsibility of integrated care board and general practitioners use their professional judgement in diagnosing and treating this condition.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 10/07/2023 16:17:59 answering member 4492 label Biography information for Maria Caulfield
tabling member	1453 label Biography information for Andrew Selous

1642393

registered interest
date	06/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Urinary Tract Infections: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the cost to the public purse was of NHS treatment for people admitted to hospital with urinary tract infections in each financial year between 2018-19 and 2021-22.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	187916
answer	answer is ministerial correction date of answer 13/06/2023 answer text <p>The information requested is not held centrally.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 13/06/2023 11:25:17 answering member 4527 label Biography information for Helen Whately
tabling member	1453 label Biography information for Andrew Selous

1639611

registered interest
date	23/05/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Urinary Tract Infections: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people are admitted to hospital each year with urinary tract infections; what the cost was to the public purse of the NHS of treating people with urinary tract infections in the last financial year; and whether the NHS plans to take steps to improve options for community-based services to treat urinary tract infections.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	186316
answer	answer is ministerial correction date of answer 02/06/2023 answer text <p>The following table shows the number of people admitted to hospital each year in the last five years with urinary tract infections (UTIs).</p><table><tbody><tr><td><p>Year</p></td><td><p>Admissions</p></td></tr><tr><td><p>2018/19</p></td><td><p>184,794</p></td></tr><tr><td><p>2019/20</p></td><td><p>179,785</p></td></tr><tr><td><p>2020/21</p></td><td><p>135,594</p></td></tr><tr><td><p>2021/22</p></td><td><p>152,695</p></td></tr></tbody></table><p><br> Source: Hospital Episode Statistics (HES), NHS England</p><p>Data for 2021/22 is latest data available. We cannot provide data on the total cost to the NHS of treating patients with UTI in the last financial year (2022/23). <br> <br> NHS England published on 9 May 2023 its Delivery plan for recovering access to primary care. This sets out proposals to improve options for community-based services to treat urinary tract infections. Appropriately trained community pharmacists will be commissioned to provide a clinical service to care for patients with urinary symptoms, providing timely access to assessment, information and advice.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 02/06/2023 11:06:52 answering member 4527 label Biography information for Helen Whately
tabling member	1453 label Biography information for Andrew Selous

1639613

registered interest
date	23/05/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help prevent people from developing dementia.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	186317
answer	answer is ministerial correction date of answer 26/05/2023 answer text <p>We are focusing on the major conditions which contribute to early mortality and reduce years of good health and taking action to reduce the risk factors for cardiovascular disease that are also risk factors for vascular dementia. For example, encouraging people in mid-life to stop smoking, reduce their alcohol consumption and improve their diet to help reduce the risk of developing dementia, disability and frailty in later life.</p><p>The Government recently announced that it will publish a Major Conditions Strategy which will set out a strong and coherent policy agenda that sets out a shift to integrated, whole-person care. An interim report will be published in the summer.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 26/05/2023 13:17:59 answering member 4527 label Biography information for Helen Whately
tabling member	1453 label Biography information for Andrew Selous

1610397

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Incontinence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress has been made in monitoring the implementation of the Excellence in Continence Care Guidelines.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	180530
answer	answer is ministerial correction date of answer 25/04/2023 answer text <p>NHS England does not monitor the implementation of the Excellence in Continence Care Guidelines. NHS England will consider next steps on Excellence in Continence Care through its National Bladder and Bowel Health Project and will report shortly. NHS England does not currently have any plans to commission a new Continence Care Audit.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 180531 question first answered 25/04/2023 11:08:12 answering member 4527 label Biography information for Helen Whately
tabling member	1453 label Biography information for Andrew Selous

1610398

registered interest
date	14/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Incontinence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to commission a new Continence Care Audit.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	180531
answer	answer is ministerial correction date of answer 25/04/2023 answer text <p>NHS England does not monitor the implementation of the Excellence in Continence Care Guidelines. NHS England will consider next steps on Excellence in Continence Care through its National Bladder and Bowel Health Project and will report shortly. NHS England does not currently have any plans to commission a new Continence Care Audit.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 180530 question first answered 25/04/2023 11:08:12 answering member 4527 label Biography information for Helen Whately
tabling member	1453 label Biography information for Andrew Selous

1566401

registered interest
date	12/01/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether there are patient representatives on the boards of integrated care boards and on primary care, commissioning and assurance committees; and if he will make a statement.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	122077
answer	answer is ministerial correction date of answer 25/01/2023 answer text <p>The Health and Care Act 2022 sets out minimum membership requirements for integrated care boards (ICBs) that includes representatives from NHS Trusts, Primary Care and Local Authorities and does not mandate patient representation on ICBs. However, the local areas can, by local agreement, go beyond the legislative minimum requirements in order to address their local needs.</p><p> </p><p>Primary care, commissioning and assurance committees are non-statutory ICB committees. There are no national requirements set by NHS England for how ICBs constitute any committee responsible for the discharge of any delegated primary care responsibilities including patient representation.</p><p>ICBs’ constitutions are expected to include principles and arrangements for how the ICB will work with patients and communities. ICBs are also legally bound (under section 13Q of the National Health Service Act 2006) to involve the public in the commissioning of services for National Health Service patients.</p><p>Currently there are no plans for the Secretary of State to make a statement to mandate any additional requirements for ICBs.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 25/01/2023 17:57:10 answering member 4527 label Biography information for Helen Whately previous answer version 47775 answering member constituency Harborough answering member printed Neil O'Brien answering member 4679
tabling member	1453 label Biography information for Andrew Selous